Search results for " Remicade" in Articles / App Notes
Article
Biosimilars: Making the Switch Comes with Challenges
In the Nordic countries and the UK, the variation in prescribing of the product, which competes with Johnson & Johnson’s Remicade, a treatment for rheumatoid arthritis and similar conditions, has had …
Article
The Bullish Outlook for Biosimilars
Originator manufacturers
Global sales of originator biologics such as Remicade (infliximab) continue to flourish. In fact, the product saw 7% growth in sales in late 2014, pushing total annual rev…
Article
Monoclonal Antibodies Key to Unlocking the Biosimilars Market
Celltrion will be launching Remsima in France, Germany, Italy, Spain, and the United Kingdom (the EU5) in 2015, when J&J’s recently won patent extension for Remicade elapses in February of that year.
…
Article
Trends in BioPharma Approvals in 2013
It is a biosimilar version of Remicade, which has been on the market in Europe since 1999 and is used to treat a wide range of inflammatory conditions. Remicade generated annual global revenues in the…
Article
N-Glycan Analysis of Biotherapeutic Proteins
CHO cells are also capable of producing the α-gal epitope (23), although interestingly, IgE binding is not observed when α-gal is present on Fc N-glycans of Remicade (infliximab) and Orencia (abatacep…
Article
Addressing the Challenges in Downstream Processing Today and Tomorrow
Newer classes of biotherapies will require innovations in processing technology.
By Glen R. Bolton, Bernard N. Violand, Richard S. Wright, Shujun Sun, Khurram M. Sunasara, Kathleen Watson, Johna…